sahrazanetti's library 80 articles Export

	An Inhibitory Ig Superfamily Protein Expressed by Lymphocytes and APCs Is Also an Early Marker of Thymocyte Positive Selection [My Copy] J Immunol, Vol. 172, No. 10. (15 May 2004), pp. 5931-5939. by Peggy Han, Olivia D. Goularte, Kevin Rufner, Beverley Wilkinson, Jonathan Kaye posted to apc tolerance by sahrazanetti on 2009-04-27 04:16:29 as
	Cutting Edge: A Critical Role of B and T Lymphocyte Attenuator in Peripheral T Cell Tolerance Induction [My Copy] J Immunol, Vol. 182, No. 8. (15 April 2009), pp. 4516-4520. by Xikui Liu, Maria Alexiou, Natalia Martin-Orozco, et al.Yeonseok Chung, Roza I. Nurieva, Li Ma, Qiang Tian, George Kollias, Sijie Lu, Daniel Graf, Chen Dong posted to autoimmunity b-cells t-cells tolerance by sahrazanetti on 2009-04-27 04:13:27 as
	Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. [My Copy] J Exp Med, Vol. 186, No. 2. (21 July 1997), pp. 239-245. by C. Kurts, H. Kosaka, F. R. Carbone, J. F. Miller, W. R. Heath posted to autoimmunity cd8 mhc t-cells tolerance by sahrazanetti on 2009-04-27 04:09:47 as along with 1 person ivodopi8
	The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance [My Copy] Nature Immunology, Vol. 10, No. 1. (16 November 2008), pp. 92-100. by Alejandro Villagra, Fengdong Cheng, Hong-Wei Wang, et al.Ildelfonso Suarez, Michelle Glozak, Michelle Maurin, Danny Nguyen, Kenneth L. Wright, Peter W. Atadja, Kapil Bhalla, Javier Pinilla-Ibarz, Edward Seto, Eduardo M. Sotomayor posted to autoimmunity tolerance by sahrazanetti on 2009-04-27 04:06:45 as
	From immunity to tolerance through HDAC [My Copy] Nature Immunology, Vol. 10, No. 1., pp. 13-14. by Katia Georgopoulos posted to autoimmunity tolerance by sahrazanetti on 2009-04-27 04:06:01 as
	Origin of the sharp boundary that discriminates positive and negative selection of thymocytes. [My Copy] Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 2. (13 January 2009), pp. 528-533. by A. Prasad, J. Zikherman, J. Das, J. P. Roose, A. Weiss, A. K. Chakraborty posted to autoimmunity mhc tolerance by sahrazanetti on 2009-04-27 03:58:06 as along with 1 person allmensch
	Molecular mechanisms involved in the etiology and pathogenesis of autoimmune diseases [My Copy] Journal of Molecular Medicine, Vol. 70, No. 9. (1 September 1992), pp. 756-765. by M. Trucco posted to autoimmunity by sahrazanetti on 2009-04-17 02:02:05 as
	Regulatory T cells in human autoimmune diseases. [My Copy] Springer seminars in immunopathology, Vol. 28, No. 1. (August 2006), pp. 63-76. by T. R. Torgerson posted to autoimmunity t-cells by sahrazanetti on 2009-04-17 01:38:54 as along with 1 person Zephyrus
	Role of regulatory T-cells in autoimmunity. [My Copy] Clinical science (London, England : 1979), Vol. 116, No. 8. (April 2009), pp. 639-649. by R. J. Mellanby, D. C. Thomas, J. Lamb posted to autoimmunity t-cells by sahrazanetti on 2009-04-17 01:31:37 as
	Copy number variation in the human genome and its implication in autoimmunity. [My Copy] Clinical and experimental immunology, Vol. 156, No. 1. (April 2009), pp. 12-16. by H. Schaschl, T. J. Aitman, T. J. Vyse posted to autoimmunity by sahrazanetti on 2009-04-17 01:25:39 as along with 6 people leemachado shikin rdiaz noushin Zephyrus pkonings
	Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. [My Copy] Pharmacology & therapeutics, Vol. 111, No. 3. (September 2006), pp. 893-908. by M. J. Chapman posted to atherosclerosis hdl by sahrazanetti on 2009-02-28 12:29:55 as
	Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. [My Copy] Pharmacological reviews, Vol. 58, No. 3. (September 2006), pp. 342-374. by A. Kontush, M. J. Chapman posted to atherosclerosis hdl by sahrazanetti on 2009-02-28 12:22:23 as
	High-density lipoprotein function recent advances. [My Copy] Journal of the American College of Cardiology, Vol. 46, No. 10. (15 November 2005), pp. 1792-1798. by B. J. Ansell, K. E. Watson, A. M. Fogelman, M. Navab, G. C. Fonarow posted to atherosclerosis hdl by sahrazanetti on 2009-02-28 12:11:16 as
	High-density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study. [My Copy] Current opinion in cardiology, Vol. 19, No. 4. (July 2004), pp. 385-391. by B. F. Asztalos, posted to atherosclerosis hdl by sahrazanetti on 2009-02-28 12:06:45 as
	Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. [My Copy] Current opinion in cardiology, Vol. 19, No. 4. (July 2004), pp. 366-373. by C. D. Meyers, M. L. Kashyap posted to atherosclerosis hdl by sahrazanetti on 2009-02-28 12:05:18 as
	Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence [My Copy] Expert Review of Cardiovascular Therapy, Vol. 3, No. 6. (November 2005), pp. 1071-1086. by Jerzy-Roch Nofer, Michael Walter, Gerd Assmann posted to apoa1 atherosclerosis by sahrazanetti on 2009-02-28 12:03:41 as
	High-density lipoproteins, inflammation and oxidative stress. [My Copy] Clinical science (London, England : 1979), Vol. 116, No. 2. (January 2009), pp. 87-98. by F. Tabet, K. A. Rye posted to apoa1 atherosclerosis by sahrazanetti on 2009-02-28 12:01:47 as
	ApoB/ApoA1 ratio and subclinical atherosclerosis. [My Copy] International angiology : a journal of the International Union of Angiology, Vol. 27, No. 1. (February 2008), pp. 74-80. by A. Panayiotou, M. Griffin, N. Georgiou, et al.D. Bond, T. Tyllis, C. Tziakouri-Shiakalli, C. Fessas, A. Nicolaides posted to apoa1 atherosclerosis by sahrazanetti on 2009-02-28 09:10:41 as
	Cholesterol oxidation products and disease: an emerging topic of interest in medicinal chemistry. [My Copy] Current medicinal chemistry, Vol. 16, No. 6. (2009), pp. 685-705. by B. Sottero, P. Gamba, S. Gargiulo, G. Leonarduzzi, G. Poli posted to cholesterol by sahrazanetti on 2009-02-28 09:06:19 as
	Untangling the role of amyloid in atherosclerosis. [My Copy] Current opinion in lipidology, Vol. 17, No. 5. (October 2006), pp. 541-547. by G. J. Howlett, K. J. Moore posted to amyloid atherosclerosis by sahrazanetti on 2009-02-28 08:26:13 as along with 1 person roslyn
	Acute Effects of Intravenous Infusion of ApoA1/Phosphatidylcholine Discs on Plasma Lipoproteins in Humans [My Copy] Arterioscler Thromb Vasc Biol, Vol. 19, No. 4. (1 April 1999), pp. 979-989. by M. N. Nanjee, J. E. Doran, P. G. Lerch, N. E. Miller posted to apoa1 human lipoprotein phosphatidylcholine by sahrazanetti on 2009-02-24 09:21:21 as
	How cholesterol homeostasis is regulated by plasma membrane cholesterol in excess of phospholipids [My Copy] Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 32. (2004), pp. 11664-11667. by Yvonne Lange, Jin Ye, Theodore L. Steck posted to no-tag by sahrazanetti on 2009-02-24 07:54:45 as
	Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. [My Copy] Drug metabolism and disposition: the biological fate of chemicals, Vol. 35, No. 9. (September 2007), pp. 1672-1678. by S. Woo, W. J. Jusko posted to allometric_scaling biologics pharmacokinetics by sahrazanetti on 2008-11-07 07:59:57 as
	Drug interaction studies of therapeutic proteins or monoclonal antibodies. [My Copy] Journal of clinical pharmacology, Vol. 47, No. 12. (December 2007), pp. 1540-1554. by I. Mahmood, M. D. Green posted to antibody biologics pharmacokinetics by sahrazanetti on 2008-10-23 12:05:12 as along with 1 person roslyn
	New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. [My Copy] Journal of clinical pharmacology, Vol. 48, No. 6. (June 2008), pp. 662-670. by S. M. Huang, J. M. Strong, L. Zhang, et al.K. S. Reynolds, S. Nallani, R. Temple, S. Abraham, S. A. Habet, R. K. Baweja, G. J. Burckart, S. Chung, P. Colangelo, D. Frucht, M. D. Green, P. Hepp, E. Karnaukhova, H. S. Ko, J. I. Lee, P. J. Marroum, J. M. Norden, W. Qiu, A. Rahman, S. Sobel, T. Stifano, K. Thummel, X. X. Wei, S. Yasuda, J. H. Zheng, H. Zhao, L. J. Lesko posted to assignment_4 by sahrazanetti on 2008-10-22 07:34:41 as along with 1 person roslyn
	New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. [My Copy] Annual review of medicine, Vol. 52 (2001), pp. 239-257. by S. Mudaliar, R. R. Henry posted to assignment_4 by sahrazanetti on 2008-10-21 14:10:19 as
	THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE [My Copy] Drug Metab Dispos, Vol. 31, No. 7. (1 July 2003), pp. 815-832. by Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf, et al.Volker Fischer, Lawrence Gan, Scott Grimm, John Kao, Peter S. King, Gerald Miwa, Lan Ni, Gondi Kumar, James Mcleod, Scott R. Obach, Stanley Roberts, Amy Roe, Anita Shah, Fred Snikeris, John T. Sullivan, Donald Tweedie, Jose M. Vega, John Walsh, Steven A. Wrighton posted to assignment_4 by sahrazanetti on 2008-10-20 04:26:49 as
	Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction [My Copy] Drug Metab Dispos, Vol. 34, No. 10. (1 October 2006), pp. 1742-1748. by Sharon L. Ripp, Jessica B. Mills, Odette A. Fahmi, et al.Kristen A. Trevena, Jennifer L. Liras, Tristan S. Maurer, Sonia M. de Morais posted to assignment_4 by sahrazanetti on 2008-10-20 04:23:36 as
	Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition [My Copy] Drug Metab Dispos, Vol. 31, No. 4. (1 April 2003), pp. 439-446. by Jasminder Sahi, Christopher B. Black, Geraldine A. Hamilton, et al.Xianxian Zheng, Summer Jolley, Kelly A. Rose, Darryl Gilbert, Edward L. Lecluyse, Michael W. Sinz posted to assignment_4 by sahrazanetti on 2008-10-20 04:13:04 as
	An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. [My Copy] Toxicology, Vol. 216, No. 2-3. (15 December 2005), pp. 154-167. by L. Vignati, E. Turlizzi, S. Monaci, P. Grossi, R. Kanter, M. Monshouwer posted to assignment_4 by sahrazanetti on 2008-10-20 04:09:53 as
	Pharmacogenetics of glucose-lowering drug treatment: a systematic review. [My Copy] Molecular diagnosis & therapy, Vol. 11, No. 5. (2007), pp. 291-302. by O. Bozkurt, A. de Boer, D. E. Grobbee, E. R. Heerdink, H. Burger, O. H. Klungel posted to assignment_4 by sahrazanetti on 2008-10-20 03:52:30 as
	The allometric approach for interspecies scaling of pharmacokinetic parameters [My Copy] Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, Vol. 103, No. 2. (October 1992), pp. 249-253. by W. Ritschel posted to allometric_scaling pharmacokinetics by sahrazanetti on 2008-10-19 11:44:24 as
	Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. [My Copy] The Journal of pharmacology and experimental therapeutics, Vol. 288, No. 1. (January 1999), pp. 371-378. by Y. S. Lin, C. Nguyen, J. L. Mendoza, et al.E. Escandon, D. Fei, Y. G. Meng, N. B. Modi posted to allometric_scaling antibody pharmacokinetics by sahrazanetti on 2008-10-19 10:39:05 as
	Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. [My Copy] European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Vol. 21, No. 2-3. (February 2004), pp. 261-270. by J. Duconge, R. Castillo, T. Crombet, et al.D. Alvarez, J. Matheu, G. Vecino, K. Alonso, I. Beausoleil, C. Valenzuela, M. A. Becquer, E. Fernández-Sánchez posted to allometric_scaling antibody pharmacokinetics by sahrazanetti on 2008-10-19 10:35:42 as
	Inhibitory effect of troglitazone on glucuronidation catalyzed by human uridine diphosphate-glucuronosyltransferase 1A6 [My Copy] European Journal of Clinical Pharmacology, Vol. 56, No. 12. (1 March 2001), pp. 893-895. by Masaki Ito, Kazuo Yamamoto, Hiroshi Sato, Yoshihide Fujiyama, Tadao Bamba posted to assignment_4 by sahrazanetti on 2008-10-16 14:38:26 as
	Coadministration of acetaminophen and troglitazone: pharmacokinetics and safety [My Copy] J Clin Pharmacol, Vol. 38, No. 9. (1 September 1998), pp. 819-824. by M. A. Young, S. Lettis, R. Eastmond posted to assignment_4 by sahrazanetti on 2008-10-16 14:33:52 as
	Identification of glutathione conjugates of troglitazone in human hepatocytes [My Copy] Chemico-Biological Interactions, Vol. 142, No. 1-2. (10 November 2002), pp. 83-97. by S. Prabhu, A. Fackett, S. Lloyd, et al.H. Mcclellan, C. Terrell, P. Silber, A. Li posted to assignment_4 by sahrazanetti on 2008-10-16 14:31:55 as
	Troglitazone Induces CYP3A4 Activity Leading to Falsely Abnormal Dexamethasone Suppression Test [My Copy] J Clin Endocrinol Metab, Vol. 88, No. 7. (1 July 2003), pp. 3113-3116. by Eleni V. Dimaraki, Craig A. Jaffe posted to assignment_4 by sahrazanetti on 2008-10-16 14:27:58 as
	Potential interaction between troglitazone and atorvastatin [My Copy] Journal of Clinical Pharmacy & Therapeutics, Vol. 25, No. 4. (2000), pp. 279-282. by Ditusa, Bown A. Luzier posted to assignment_4 by sahrazanetti on 2008-10-16 14:26:14 as
	Clinical Pharmacokinetics of Troglitazone [My Copy] Clinical Pharmacokinetics (August 1999), pp. 91-104. by C. M. Loi, M. Young, E. Randinitis, A. Vassos, J. R. Koup posted to assignment_4 by sahrazanetti on 2008-10-16 14:22:37 as
	Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? [My Copy] Biopharmaceutics & drug disposition, Vol. 25, No. 4. (May 2004), pp. 177-186. by J. Ducongé, E. Fernández-Sánchez, D. Alvarez posted to allometric_scaling biologics pharmacokinetics by sahrazanetti on 2008-10-16 12:00:39 as
	Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. [My Copy] Pharmaceutical research, Vol. 15, No. 5. (May 1998), pp. 726-733. by M. C. Grès, B. Julian, M. Bourrié, et al.V. Meunier, C. Roques, M. Berger, X. Boulenc, Y. Berger, G. Fabre posted to absorption cell_line humans in_vitro by sahrazanetti on 2008-10-14 18:02:56 as
	Physiologically based approaches towards the prediction of pharmacokinetics: in vitroin vivo extrapolation [My Copy] Expert Opinion on Drug Metabolism and Toxicology, Vol. 3, No. 6. (December 2007), pp. 865-878. by De Buck, S. Stefan, Mackie, E. Claire posted to in_vitro in_vivo pharmacokinetics by sahrazanetti on 2008-10-12 10:39:55 as
	Prediction of human pharmacokinetics gastrointestinal absorption [My Copy] Journal of Pharmacy and Pharmacology, Vol. 59, No. 7. (July 2007), pp. 905-916. by Fagerholm, Urban posted to absorption humans pharmacokinetics by sahrazanetti on 2008-10-11 18:21:51 as
	Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. [My Copy] Current drug metabolism, Vol. 7, No. 2. (February 2006), pp. 165-182. by S. S. Singh posted to pharmacokinetics preclinical by sahrazanetti on 2008-10-11 17:59:10 as
	Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. [My Copy] Chem Biol Interact, Vol. 168, No. 1. (20 May 2007), pp. 30-50. by M. J. Gómez-Lechón, J. V. Castell, M. T. Donato posted to in_vitro in_vivo metabolism toxicology by sahrazanetti on 2008-10-11 17:54:33 as along with 1 person guhjy
	Role of pharmacokinetics and metabolism in drug discovery and development. [My Copy] Pharmacological reviews, Vol. 49, No. 4. (December 1997), pp. 403-449. by J. H. Lin, A. Y. Lu posted to drug_development nce pharmacokinetics review by sahrazanetti on 2008-10-11 17:42:18 as along with 1 person roslyn
	Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine. [My Copy] Vaccine, Vol. 23, No. 20. (8 April 2005), pp. 2628-2638. by L. M. Tatalick, C. J. Gerard, R. Takeya, et al.D. N. Price, B. A. Thorne, L. M. Wyatt, P. Anklesaria posted to cell_line characterization recombinant safety by sahrazanetti on 2008-10-07 07:24:14 as
	Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. [My Copy] Glycobiology, Vol. 17, No. 5. (May 2007), pp. 529-540. by A. J. Jones, D. I. Papac, E. H. Chin, et al.R. Keck, S. A. Baughman, Y. S. Lin, J. Kneer, J. E. Battersby posted to humans pharmacokinetics primate by sahrazanetti on 2008-10-07 03:43:26 as
	Comparative pharmacokinetics of frusemide in female rhesus monkeys, cynomolgus monkeys and baboons. [My Copy] Comparative biochemistry and physiology. C: Comparative pharmacology, Vol. 71C, No. 1. (1982), pp. 89-93. by E. Doyle, L. F. Chasseaud, J. N. Miller posted to pharmacokinetics preclinical primate by sahrazanetti on 2008-10-07 03:36:11 as

Note: You may cite this page as: http://www.citeulike.org/user/sahrazanetti

Result page: 1 2 Next

biologics	23
pharmacokinetics	20
immunogenicity	16
assignment_4	13
antibody	9
atherosclerosis	9
autoimmunity	9
preclinical	6
tolerance	6
allometric_scaling	5
hdl	5
humans	5
animals	4
apoa1	4
primate	4
t-cells	4
in_vitro	3
toxicology	3
absorption	2
cell_line	2
in_vivo	2
mhc	2
nce	2
pegylation	2
recombinant	2
reproductive	2
amyloid	1
apc	1
b	1
b-cells	1
biodrugs	1
cd8	1
characterization	1
cholesterol	1
drug_development	1
human	1
lipoprotein	1
metabolism	1
microdosing	1
modeling	1
nonclinical	1
phosphatidylcholine	1
regulatory	1
review	1
safety	1
vaccine	1

sahrazanetti's library 80 articles Export

sahrazanetti's tags